Antibacterial Therapy for Nosocomial Pneumonias Caused by Multidrug-Resistant Microorganisms in Critical 1ll Patients
https://doi.org/10.15360/1813-9779-2007-3-90
Abstract
References
1. Link H., Maschmeyer G., Mejer P. et al.
2. Sanders C. C., Sanders W. E.Emergence of resistance during therapy with newer B-lactam antibiotics: role of inducible B-lactamases and implications for the future. Rev. Infect. Dis. 1983: 639—648
3. Pizzo P. A., Hathorn J. W., HiemenzJ. et al.A randomize trial comparing ceftazidime alone with combination antibiotic therapy in cancer patients with fever and neutropenia. N. Engl. J. Med. 1986; 315: 552—558
4. EORTC International аntimicrobial therapy co-operative group. Ceftazidim combined with short or long course of amicacin for empirical therapy of gram-negative bacteremia in cancer patients with neu-tropenia. N. Engl. J. Med. 1987; 317: 1692—1698
5. Thornsberry C., Yee Y. C.Comparative activity of eight antimicrobial agents against clinical bacterial isolates from the United States, measured by two methods. Am. J. Med. 1996; 100 (Suppl. 6A): 26S—38S.
6. Hughes W. T., Armstrong D., Bodey G. P. et al.Guidelines for the use of antimicrobial agents in neutropenic patients with unexplained fever. J. Infect. Dis. 1990; 161: 381—39
7. Sanders C. C.Cefepime: the next generation? Clin. Infect. Dis. 1993; 17: 369—370.
8. Biron P., Fuhrman C., Cure H. et al.CEMIC (Study group of infectious disease in cancer) Cefepime versus imipenem/cilastatin as the empirical monotherapy of 400 febrile episodes in patients with short term neu-tropenia J. Antimicr. Chemother. 1998; 42: 511—51
9. Barbhaya R. H., Forgue S. T., Gleason K. R. et al.Pharmacokinetics of cefepime after single and multiple intravenous administrations in healthy subjects. Antimicr. Ag. Chemother. 1992; 36: 552—557.
10. Ramphal R.Innovative therapeutic approach with cefepime in the empirical treatment of febrile neutropenia. Infect. Dis. In Clin.Pract. (IDCP) 2000; Special suppl. Symposium: The expanding role of cefepime as empiric therapy: 2—4.
11. Neu H. C., Chin N. X., Jules K. et al.The activity of BMY 28142 a new broad spectrum /З-lactamase stable cephalosporin. J. Antimicr. Chemother. 1986; 17: 941-452
12. Cometa A., Zinner S., de Bock T. et al.Piperacillin — Tazobactam plus Amikacin versus Ceftazidim plus Amikacin as empiric therapy for fever in granulocytopenic patients with cancer. Antimicrob. Ag. Chemother. 1995; 39: 445—452.
13. Ramphal R., Gulcap R., Rotstain C. et al.Clinical experience with single agent and combination regimens in the management of infection in the febrile neutropenic patient. Am. J. Med. 1996; 100 (Suppl. 6a): 83—88.
14. Pizzo P.А., Armstrong D., Bodey G. et al.The design, analysis, and reporting of clinical trials on the empirical antibiotic management of the neutropenic patient/ Report of consensus panel. JAC 1990; 161: 397—401.
15. Cometa A., Viscoli C., Castagnola E. et al.Empirical treatment of fever in neutropenic children: the role of carbapenems. Pediatr. Inf.Dis. J. 1996; 15: 744—748.
Review
For citations:
Moroz V.V., Marchenkov Yu.V., Lysenko D.V., Karpun N.A., Morozova O.A. Antibacterial Therapy for Nosocomial Pneumonias Caused by Multidrug-Resistant Microorganisms in Critical 1ll Patients . General Reanimatology. 2007;3(3):90. https://doi.org/10.15360/1813-9779-2007-3-90
Email this article 